Trinity Biotech's profit rises 111%:
This article was originally published in Clinica
Irish company Trinity Biotech, a manufacturer of diagnostic products, saw net profit for 1998 increase by 111% to $2.6 million on revenues of $23.2 million, up 38%. The Dublin-based company which makes products for the point-of-care, self-testing and clinical laboratory markets, has 124 products on the market, compared with only six products two years ago. During the year, the company bought four product lines and launched eight new products.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.
The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. Scrip reviews the leading drug developers in this space.